Complement and contact system activation in acute congestive heart failure patients

C. Suffritti, E. Tobaldini, R. Schiavon, S. Strada, L. Maggioni, S. Mehta, G. Sandrone, E. Toschi-Dias, M. Cicardi, N. Montano

Research output: Contribution to journalArticle

Abstract

Recent experimental data indicate a pathogenic role of complement activation in congestive heart failure (CHF). The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF. Forty-two of 80 consecutive patients admitted at our hospital with confirmed diagnosis of acute CHF were enrolled. They underwent blood sampling within 24 h from admission (T0) and at clinical stability (T1). Patients were stratified for ejection fraction (EF) based on echocardiographic test. We measured plasma levels of C3, C4, sC5b-9 and cleaved high molecular weight kininogen (contact activation marker). At T1, C3 levels increased significantly compared to T0 (97 ± 2 versus 104 ± 3% of total pooled plasma, P<0·01). Classifying patients according to EF, only patients with preserved EF presented a significant increase of C3 from T0 to T1 (99 ± 3 versus 108 ± 4%, P = 0·03). When the sample was stratified according to clinical outcome, C3 (98 ± 3 versus 104 ± 4%, P = 0·03) and sC5b-9 levels (204 ± 10 versus 230 ± 11 ng/ml, P = 0·03) were increased in patients who had positive outcome after hospitalization. CHF patients with preserved EF and positive outcome after hospitalization showed higher levels of sC5b-9 in the T1 period compared with T0 (211 ± 14 versus 243 ± 14 ng/ml, P = 0·04). Our results suggest that the complement system reacts differently if CHF occurs with preserved or reduced EF. This finding is interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.

Original languageEnglish
Pages (from-to)251-257
JournalClinical and Experimental Immunology
Volume190
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Heart Failure
Complement Activation
Hospitalization
High Molecular Weight Kininogens
Epidemiology

Keywords

  • Complement system
  • Contact system
  • Heart failure
  • Immune system
  • Ventricular function

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Complement and contact system activation in acute congestive heart failure patients. / Suffritti, C.; Tobaldini, E.; Schiavon, R.; Strada, S.; Maggioni, L.; Mehta, S.; Sandrone, G.; Toschi-Dias, E.; Cicardi, M.; Montano, N.

In: Clinical and Experimental Immunology, Vol. 190, No. 2, 2017, p. 251-257.

Research output: Contribution to journalArticle

Suffritti, C, Tobaldini, E, Schiavon, R, Strada, S, Maggioni, L, Mehta, S, Sandrone, G, Toschi-Dias, E, Cicardi, M & Montano, N 2017, 'Complement and contact system activation in acute congestive heart failure patients', Clinical and Experimental Immunology, vol. 190, no. 2, pp. 251-257. https://doi.org/10.1111/cei.13011
Suffritti, C. ; Tobaldini, E. ; Schiavon, R. ; Strada, S. ; Maggioni, L. ; Mehta, S. ; Sandrone, G. ; Toschi-Dias, E. ; Cicardi, M. ; Montano, N. / Complement and contact system activation in acute congestive heart failure patients. In: Clinical and Experimental Immunology. 2017 ; Vol. 190, No. 2. pp. 251-257.
@article{099dcb528a874b39bb02446e722333db,
title = "Complement and contact system activation in acute congestive heart failure patients",
abstract = "Recent experimental data indicate a pathogenic role of complement activation in congestive heart failure (CHF). The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF. Forty-two of 80 consecutive patients admitted at our hospital with confirmed diagnosis of acute CHF were enrolled. They underwent blood sampling within 24 h from admission (T0) and at clinical stability (T1). Patients were stratified for ejection fraction (EF) based on echocardiographic test. We measured plasma levels of C3, C4, sC5b-9 and cleaved high molecular weight kininogen (contact activation marker). At T1, C3 levels increased significantly compared to T0 (97 ± 2 versus 104 ± 3{\%} of total pooled plasma, P<0·01). Classifying patients according to EF, only patients with preserved EF presented a significant increase of C3 from T0 to T1 (99 ± 3 versus 108 ± 4{\%}, P = 0·03). When the sample was stratified according to clinical outcome, C3 (98 ± 3 versus 104 ± 4{\%}, P = 0·03) and sC5b-9 levels (204 ± 10 versus 230 ± 11 ng/ml, P = 0·03) were increased in patients who had positive outcome after hospitalization. CHF patients with preserved EF and positive outcome after hospitalization showed higher levels of sC5b-9 in the T1 period compared with T0 (211 ± 14 versus 243 ± 14 ng/ml, P = 0·04). Our results suggest that the complement system reacts differently if CHF occurs with preserved or reduced EF. This finding is interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.",
keywords = "Complement system, Contact system, Heart failure, Immune system, Ventricular function",
author = "C. Suffritti and E. Tobaldini and R. Schiavon and S. Strada and L. Maggioni and S. Mehta and G. Sandrone and E. Toschi-Dias and M. Cicardi and N. Montano",
year = "2017",
doi = "10.1111/cei.13011",
language = "English",
volume = "190",
pages = "251--257",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Complement and contact system activation in acute congestive heart failure patients

AU - Suffritti, C.

AU - Tobaldini, E.

AU - Schiavon, R.

AU - Strada, S.

AU - Maggioni, L.

AU - Mehta, S.

AU - Sandrone, G.

AU - Toschi-Dias, E.

AU - Cicardi, M.

AU - Montano, N.

PY - 2017

Y1 - 2017

N2 - Recent experimental data indicate a pathogenic role of complement activation in congestive heart failure (CHF). The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF. Forty-two of 80 consecutive patients admitted at our hospital with confirmed diagnosis of acute CHF were enrolled. They underwent blood sampling within 24 h from admission (T0) and at clinical stability (T1). Patients were stratified for ejection fraction (EF) based on echocardiographic test. We measured plasma levels of C3, C4, sC5b-9 and cleaved high molecular weight kininogen (contact activation marker). At T1, C3 levels increased significantly compared to T0 (97 ± 2 versus 104 ± 3% of total pooled plasma, P<0·01). Classifying patients according to EF, only patients with preserved EF presented a significant increase of C3 from T0 to T1 (99 ± 3 versus 108 ± 4%, P = 0·03). When the sample was stratified according to clinical outcome, C3 (98 ± 3 versus 104 ± 4%, P = 0·03) and sC5b-9 levels (204 ± 10 versus 230 ± 11 ng/ml, P = 0·03) were increased in patients who had positive outcome after hospitalization. CHF patients with preserved EF and positive outcome after hospitalization showed higher levels of sC5b-9 in the T1 period compared with T0 (211 ± 14 versus 243 ± 14 ng/ml, P = 0·04). Our results suggest that the complement system reacts differently if CHF occurs with preserved or reduced EF. This finding is interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.

AB - Recent experimental data indicate a pathogenic role of complement activation in congestive heart failure (CHF). The aim of this study was to evaluate contact and complement systems activation in patients hospitalized for an acute episode of CHF. Forty-two of 80 consecutive patients admitted at our hospital with confirmed diagnosis of acute CHF were enrolled. They underwent blood sampling within 24 h from admission (T0) and at clinical stability (T1). Patients were stratified for ejection fraction (EF) based on echocardiographic test. We measured plasma levels of C3, C4, sC5b-9 and cleaved high molecular weight kininogen (contact activation marker). At T1, C3 levels increased significantly compared to T0 (97 ± 2 versus 104 ± 3% of total pooled plasma, P<0·01). Classifying patients according to EF, only patients with preserved EF presented a significant increase of C3 from T0 to T1 (99 ± 3 versus 108 ± 4%, P = 0·03). When the sample was stratified according to clinical outcome, C3 (98 ± 3 versus 104 ± 4%, P = 0·03) and sC5b-9 levels (204 ± 10 versus 230 ± 11 ng/ml, P = 0·03) were increased in patients who had positive outcome after hospitalization. CHF patients with preserved EF and positive outcome after hospitalization showed higher levels of sC5b-9 in the T1 period compared with T0 (211 ± 14 versus 243 ± 14 ng/ml, P = 0·04). Our results suggest that the complement system reacts differently if CHF occurs with preserved or reduced EF. This finding is interesting if we consider the difference in epidemiology, pathogenesis and possible therapeutic approaches of these two clinical entities.

KW - Complement system

KW - Contact system

KW - Heart failure

KW - Immune system

KW - Ventricular function

UR - http://www.scopus.com/inward/record.url?scp=85028439736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028439736&partnerID=8YFLogxK

U2 - 10.1111/cei.13011

DO - 10.1111/cei.13011

M3 - Article

AN - SCOPUS:85028439736

VL - 190

SP - 251

EP - 257

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -